Plain-English translation of NCT06607757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining with fulvestrant (a hormone therapy drug) can help treat a specific type of breast cancer called invasive lobular carcinoma better than fulvestrant alone. You would receive either the medication combination or fulvestrant by itself over a 10-week period. The researchers hope this combination will help more patients avoid chemotherapy while still achieving good treatment results.
Invasive lobular breast cancer is less responsive to standard treatments like chemotherapy, so doctors need better options to identify which patients will respond well to hormone therapy alone. Early research suggests this medication might improve treatment effectiveness in these tumors, potentially sparing some patients from more intensive chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for 10 weeks of treatment. One group would take pills (twice daily for 4 days, then 3 days off) for 2 weeks, then continue this pattern while also receiving fulvestrant injections into the muscle every 4 weeks. The other group would receive only the fulvestrant injections on the same schedule. Throughout the study, you would have blood tests and imaging to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany